These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28143868)

  • 21. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
    Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
    Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
    Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
    Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.
    Martorana E; Pirola GM; Scialpi M; Micali S; Iseppi A; Bonetti LR; Kaleci S; Torricelli P; Bianchi G
    BJU Int; 2017 Jul; 120(1):92-103. PubMed ID: 27608292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and comparison of a Chinese nomogram adding multi-parametric MRI information for predicting extracapsular extension of prostate cancer.
    Chen Y; Yu W; Fan Y; Zhou L; Yang Y; Wang H; Jiang Y; Wang X; Wu S; Jin J
    Oncotarget; 2017 Mar; 8(13):22095-22103. PubMed ID: 27564265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using support vector machine analysis to assess PartinMR: A new prediction model for organ-confined prostate cancer.
    Wang J; Wu CJ; Bao ML; Zhang J; Shi HB; Zhang YD
    J Magn Reson Imaging; 2018 Aug; 48(2):499-506. PubMed ID: 29437268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Head-to-head comparison of the Montreal nomogram with the detection of primary malignant circulating prostate cells to predict prostate cancer at initial biopsy in Chilean men with suspicion of prostate cancer.
    Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O; Badilla S
    Urol Oncol; 2015 May; 33(5):203.e19-25. PubMed ID: 25746939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
    BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.
    Okcelik S; Soydan H; Ates F; Berber U; Saygin H; Sonmez G; Karademir K
    Int Braz J Urol; 2016; 42(3):449-55. PubMed ID: 27286106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels.
    Choi MH; Lee YJ; Jung SE; Rha SE; Byun JY
    Clin Radiol; 2018 Sep; 73(9):810-817. PubMed ID: 29895386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.
    Roobol MJ; Steyerberg EW; Kranse R; Wolters T; van den Bergh RC; Bangma CH; Schröder FH
    Eur Urol; 2010 Jan; 57(1):79-85. PubMed ID: 19733959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Eur Urol; 2004 Nov; 46(5):571-8. PubMed ID: 15474265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC; Hovey R; Carroll PR; Shinohara K
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.
    Dickinson L; Ahmed HU; Hindley RG; McCartan N; Freeman A; Allen C; Emberton M; Kirkham AP
    Urol Oncol; 2017 Jan; 35(1):30.e9-30.e15. PubMed ID: 27663393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.